{
    "nct_id": "NCT04155749",
    "official_title": "Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up",
    "inclusion_criteria": "* Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has \"triple-refractory\" disease\n* Documented measurable disease\n* Adequate organ function\n* Life expectancy > 12 weeks, Eastern Cooperative Group Performance Status 0-1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Plasma Cell Leukemia or History of Plasma Cell Leukemia\n* Patients with a history of severe hypersensitivity to DMSO should be excluded\n* Contraindication to fludarabine or cyclophosphamide\n* Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities\n* Active central nervous system disease involvement by malignancy or active CNS pathology",
    "miscellaneous_criteria": ""
}